![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Retrophin’s RE-024 Gains EU Orphan Drug Status
Retrophin’s RE-024 Gains EU Orphan Drug Status
Retrophin has won EU orphan drug status for RE-024, a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration.
The FDA also awarded the candidate orphan drug designation for the same indication, as well as fast track status.
Upcoming Events
-
21Oct